John Huber, MD
Hematology & Oncology · Louisville, KYNPI 1700857315
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in KY, where the typical reported total is $4,619.
Across 85 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$267
- Beigene USA, Inc.$196
- Novartis$160
- Pfizer$143
- Regeneron Healthcare Solutions, Inc.$129
- AbbVie$117
- plus $997 from 29 others
What the payments were for
- Food & beverage$1,82091%
- Education$1648%
- Gifts$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 11 | $267 |
| Beigene USA, Inc. | 3 | $196 |
| Novartis | 8 | $160 |
| Pfizer | 8 | $143 |
| Regeneron Healthcare Solutions, Inc. | 2 | $129 |
| AbbVie | 3 | $117 |
| Daiichi Sankyo Inc. | 5 | $110 |
| Astellas Pharma US Inc | 2 | $106 |
| AstraZeneca | 5 | $95 |
| Novo Nordisk | 3 | $57 |
| Gilead(2 entities) | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Merck | 3 | $49 |
| Servier Pharmaceuticals LLC | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Amgen | 2 | $35 |
| Bayer | 2 | $30 |
| GSK | 1 | $26 |
| Tosoh Bioscience, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Seagen Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Acceleron Pharma, Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Morphosys, US Inc. | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
| Global Blood Therapeutics, Inc. | 1 | $11 |
| Biofrontera Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$117
How this compares
$2,009 in reported general payments places this provider in the 30th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 35 | $815,452 |
| BrukinsaZanubrutinib | 29 | $402,347 |
| VerzenioAbemaciclib | 13 | $198,991 |
| NinlaroIxazomib Citrate | 15 | $189,830 |
| XospataGilteritinib Fumarate | 12 | $163,695 |
| EliquisApixaban | 166 | $128,879 |
| VenclextaVenetoclax | 16 | $81,498 |
| XareltoRivaroxaban | 35 | $54,967 |
| LysodrenMitotane | 11 | $16,832 |
| Exemestane | 32 | $8,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,196 |
| Ondansetron Hcl | 45 | $7,189 |
| Hydroxyurea | 76 | $2,099 |
| Acyclovir | 89 | $1,766 |
| Anastrozole | 90 | $1,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $51 | $815,45235 claims |
| Beigene USA, Inc.Brukinsa | $196 | $402,34729 claims |
| Astellas Pharma US IncXospata | $106 | $163,69512 claims |
| PfizerEliquis | $143 | $128,879166 claims |
| AbbVieVenclexta | $117 | $81,49816 claims |
| Johnson & JohnsonXarelto | $24 | $54,96735 claims |
| GSKTrelegy Ellipta | $26 | $7,19612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Louisville
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Jeffrey HargisLouisville$450K
- Mohamed HegaziLouisville$380K
- Khuda KhanLouisville$359K
- Jaspreet GrewalLouisville$280K
- Laila AgrawalLouisville$95K
- Brian DongLouisville$31K
- Rohit KumarLouisville$31K
- Vikas SinghLouisville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.